Single-Cell Omics Market By Technology (Single-Cell Genomics, Single-Cell Transcriptomics, Single-Cell Proteomics, Single-Cell Metabolomics), By Application (Cancer Research, Neurological Research, Stem Cell Research, Immunology, Microbiology), By End-User (Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs)); Global Insights & Forecast (2024 - 2030)

As per Intent Market Research, the Single-Cell Omics Market was valued at USD 1.9 Billion in 2024-e and will surpass USD 5.3 Billion by 2030; growing at a CAGR of 18.1% during 2025 - 2030.

The single-cell omics market is experiencing rapid expansion, driven by advancements in genomic and proteomic technologies that enable high-resolution molecular analysis at the individual cell level. With increasing applications in precision medicine, cancer research, and immunology, single-cell analysis is transforming biomedical research. The rising adoption of next-generation sequencing (NGS), mass spectrometry, and microfluidic technologies is further accelerating market growth.

Single-Cell Genomics Segment Is Largest Due to Its Central Role in Disease Research

Single-cell genomics is the largest segment in the market, as it plays a crucial role in understanding genetic variations at the individual cell level. This technology is widely used in oncology, neurological research, and developmental biology to study cellular heterogeneity, disease progression, and genetic mutations. The increasing use of single-cell genomics in cancer diagnostics and precision medicine has fueled demand for advanced sequencing platforms and bioinformatics tools. Additionally, improvements in single-cell isolation techniques, such as droplet-based and microfluidic methods, are further enhancing the efficiency and scalability of genomic studies.

Cancer Research Segment Is Fastest Growing Due to Rising Demand for Precision Medicine

The cancer research segment is the fastest-growing application, driven by the need for deeper insights into tumor heterogeneity, metastasis, and drug resistance. Single-cell omics enables researchers to analyze individual cancer cells, identify unique genetic mutations, and develop targeted therapies. The growing adoption of single-cell sequencing in liquid biopsy applications, along with advancements in AI-driven data analysis, is further boosting market growth. Moreover, increasing collaborations between academic institutions and pharmaceutical companies for cancer biomarker discovery are contributing to the rapid expansion of this segment.

Pharmaceutical & Biotechnology Companies Segment Is Largest Due to Drug Discovery Advancements

Pharmaceutical and biotechnology companies represent the largest end-user segment, as single-cell omics is increasingly integrated into drug discovery, biomarker identification, and therapeutic development. The ability to analyze single-cell transcriptomes and proteomes is transforming drug screening and accelerating the development of personalized medicine. With biopharmaceutical companies investing heavily in single-cell analysis for immune-oncology and regenerative medicine, the demand for high-throughput omics platforms is steadily rising. Additionally, regulatory agencies are emphasizing the use of advanced molecular analysis in drug evaluation, further strengthening market growth.

North America Is Largest Due to Strong Research Ecosystem and Funding Support

North America dominates the single-cell omics market, driven by significant investments in life sciences research, the presence of leading biotechnology firms, and robust government funding for genomic initiatives. The region benefits from advanced healthcare infrastructure, well-established academic institutions, and increasing adoption of single-cell technologies in clinical research. Additionally, the growing number of research collaborations and public-private partnerships is fueling market expansion. The presence of major market players and rapid advancements in computational biology further contribute to North America’s leading position.

Leading Companies and Competitive Landscape

The single-cell omics market is highly competitive, with key players such as 10x Genomics, Illumina, Bio-Rad Laboratories, Fluidigm, and Thermo Fisher Scientific driving innovation. Companies are focusing on improving single-cell sequencing accuracy, expanding their bioinformatics capabilities, and launching integrated multi-omics platforms. Strategic acquisitions, funding rounds, and partnerships with research institutions are key strategies employed to strengthen market presence. With the continuous advancement of single-cell analysis technologies, the market is expected to witness sustained growth, particularly in oncology, immunology, and stem cell research applications.

List of Leading Companies:

• 10x Genomics, Inc.
• Illumina, Inc.
• Becton, Dickinson and Company (BD Biosciences)
• Fluidigm Corporation
• Qiagen N.V.
• Bio-Rad Laboratories, Inc.
• Thermo Fisher Scientific Inc.
• Pacific Biosciences of California, Inc.
• Takara Bio Inc.
• Oxford Nanopore Technologies
• Mission Bio, Inc.
• Agilent Technologies, Inc.
• PerkinElmer, Inc.
• Bruker Corporation
• Danaher Corporation

Recent Developments:

• 10x Genomics, Inc. launched a new single-cell multi-omics platform for high-resolution spatial analysis in February 2025.
• Illumina, Inc. partnered with a biotech firm to enhance single-cell sequencing workflows for drug discovery in January 2025.
• Becton, Dickinson and Company (BD Biosciences) introduced an advanced single-cell sorting system for immunology research in December 2024.
• Fluidigm Corporation expanded its single-cell proteomics product line with an upgraded mass cytometry platform in November 2024.
• Qiagen N.V. announced a strategic collaboration for developing AI-powered single-cell data analysis tools in October 2024.

Report Scope: